

PRESS RELEASE

Tandem Therapeutics AG has been accepted into the Wyss Zurich Translational Center (Wyss Zurich) as Project Tandem. The project is onboarded as of 1st April 2024. With the support of this accelerator program, providing access to world-class infrastructure and experts, as well as financial backing, Tandem Therapeutics is eager to advance translational R&D efforts aimed at developing novel peptide drug conjugates to precision target and treat fibrosis-driven diseases.

Fibrosis represents a significant unmet medical challenge, contributing to over 45% of deaths in the developed world. Progressive fibrosis leads to the disruption of organ function and represents a significant cause of morbidity and mortality globally. At Tandem Therapeutics, we aim to go beyond conventional cell targeting by harnessing the unique "mechanical fingerprint" of the extracellular matrix, known to drive disease progression.

"We extend our heartfelt gratitude to the Wyss Zurich Scientific and Evaluation Boards for guiding us to this exciting opportunity. Project Tandem would not be here without the amazing focus and drive from Team Tandem and our Advisors," says Dr Mamta Chabria, Project Leader of Project Tandem and CEO of Tandem Therapeutics AG.

Leveraging successful proof-of-concept data, Tandem Therapeutics, with the support from Wyss Zurich, aims to develop lead candidates to treat progressive lung fibrosis, a devastatingly fatal disease with no available cure.

About Tandem Therapeutics AG

Progressive fibrosis results in disruption of organ function which is a major cause of morbidity and mortality worldwide. By using evolutionarily optimized matrix targeting peptides, Tandem Therapeutics overcomes the extracellular matrix barrier to unlock the previously inaccessible multidimensional druggable space. Using a deep understanding of matrix mechanobiology and its relation to disease progression, Tandem Therapeutics is developing a pipeline of selectively targeted, efficacious, and safe therapies to treat progressive lung fibrosis. For more information, please visit www.tandem-tx.com

About Wyss Zurich Translational Center

The Wyss Zurich Translational Center (Wyss Zurich) is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of regenerative medicine, robotics, and medical devices/bionics. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise. For more information, please visit www.wysszurich.ch

Contact Information

Mamta Chabria, PhD
CEO, Tandem Therapeutics AG
Project Leader, Project Tandem, Wyss Zurich Translational Center
E-Mail: mamta.chabria@wysszurich.ch